Market Overview

UPDATE: Bank of America Upgrades Centene to Buy on Health Care Reform Tailwinds

Share:
Related CNC
Molina Healthcare's Issues Aren't Permanent, JPMorgan Says Amid Upgrade
Humana, Anthem Benefit From 'Attractive' Managed Care Sector, Jefferies Says
UnitedHealth's Q4 beat buoys peers (Seeking Alpha)

Bank of America raised its rating on Centene (NYSE: CNC) from Underperform to Buy and raised its price objective from $39 to $46.

Bank of America commented, "We are upgrading CNC shares to Buy (from Underperform) with a view that companies with Medicaid exposure should benefit from coverage expansions outlined in health care reform legislation. Specifically, the market is likely to refocus on revenue growth driven by states transitioning existing beneficiaries to HMOs (from unmanaged fee for service), dual eligible demonstrations and program enrollment that could increase 20% starting in 2014 as projected by the CBO. We are raising our P.O. to $46 (from $39) on P/E multiple expansion."

Centene Corporation closed at $39.87 on Tuesday.

Latest Ratings for CNC

DateFirmActionFromTo
Jan 2018Goldman SachsInitiates Coverage OnBuy
Nov 2017Credit SuisseInitiates Coverage OnNeutral
Oct 2017OppenheimerMaintainsOutperform

View More Analyst Ratings for CNC
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (CNC)

View Comments and Join the Discussion!